Treatment for newly diagnosed primary central nervous system lymphoma using pomadomide, rituximab, and methotrexate

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of pomadomide in combination with rituximab and methotrexate for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). It consists of a Phase I dose escalation study to determine the maximum tolerated dose of pomadomide, followed by a Phase II study to evaluate the treatment's efficacy and safety in a larger group of participants. Patients will receive a regimen of these medications over four courses, with careful monitoring for treatment response and side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histopathologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).
* The lesions were confined to the central nervous system, including the brain, spinal cord, eyes and meninges.
* Through physical examination, imaging examination (including CT, MRI, PET-CT, etc.) and bone marrow puncture examination, it was confirmed that no parts other than the central nervous system were involved.
* Patients who have not previously received chemotherapy or radiotherapy (except those with dexamethasone less than 10mg/ day (or equivalent dose) and duration less than 5 days).
* Aged between 18 and 75 (inclusive).
* Eastern Cooperative Oncology Group performance status 0 to 3.
* Measurable disease was defined as at least ≥1.0cm in short-diameter by enhanced MRI.
* Life expectancy of ≥ 3 months (in the opinion of the investigator).
* Participants must be able to understand and be willing to sign a written informed consent document.
* Participants can follow up on schedule, communicate well with the investigator and complete the trial according to the trial regulations.
* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 6 months after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 6 months after the last dose.

Exclusion Criteria:

* Have systemic lymphoma disease.
* Previous systemic or local treatment such as chemotherapy and/or radiotherapy and/or hematopoietic stem cell transplantation.
* Previous or concurrent history of other malignant tumors requiring active therapy.
* Chronic or currently active infectious diseases requiring systemic antibiotic, antifungal, or antiviral treatment (except EBV infections).
* Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, bleeding diseases, thrombotic diseases, connective tissue diseases and other diseases.
* Patients with other uncontrolled diseases that the researchers deemed unsuitable for inclusion.
* Laboratory test values at screening (unless due to lymphoma) : White blood cell count \< 3.5×109/L, neutrophils \<1.5×109/L, platelets \<80×109/L, hemoglobin \<100g/L, ALT or AST 2.5 times higher than the upper limit of normal, bilirubin 1.5 times higher than the upper limit of normal, creatinine level 1.5 times higher than the upper limit of normal.
* Presence of active hepatitis B virus(HBV) infection (HBsAg positive and HBV-DNA≥ 104), hepatitis C virus(HCV) infection, acquired and congenital immunodeficiency diseases include but not limited to HIV. HbsAg positive patients need to check HBV-DNA \< 10\^4 to be enrolled. In addition, if HBsAg is negative but HBcAb is positive (regardless of HBsAb status), HBV-DNA testing is also required, and HBV-DNA results \< 10\^4 are required to be enrolled and continue treatment and monitoring of HBV-DNA. HCV antibody positive patients need to check HCV-RNA quantitative DNA \< 10\^3 to be enrolled.
* Pregnant or lactating women.
* Those with a history of drug use or abuse were asked.
* Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol.
* Known allergy to the investigational drug or its related ingredients.
* Patients are unable to swallow capsules or suffer from diseases or conditions that severely affect gastrointestinal function, such as malabsorption syndrome, removal of the stomach or small intestine, or complete intestinal obstruction.
* Patients who cannot withstand enhanced MRI.
* Participants considered unsuitable for this clinical trial due to various other reasons.

Where it's running

• 2nd Affiliated Hospital, School of Medicine, Zhejiang University
  Hanzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xianggui Yuan, Doctor
• Email: yuanxg@zju.edu.cn
• Phone: +8613989883884

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• R-PMDT Regimen for Newly Diagnosed PCNSL

  This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07604987

• PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib for newly diagnosed primary or secondary CNS lymphoma

  This trial will test whether combining a PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib helps people with newly diagnosed primary or secondary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07410520

• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.

  Recruiting at 9 sites Phase 2/3 Huashan Hospital · Beijing and 14 other locations · NCT07185373

• Selinexor with high-dose methotrexate, rituximab, and low-dose whole-brain radiotherapy for newly diagnosed CNS lymphoma patients who can't have transplant

  We will test whether adding oral selinexor to high-dose methotrexate and rituximab followed by low-dose whole-brain radiotherapy can help people with newly diagnosed central nervous system lymphoma who are not candidates for stem cell transplant.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou · NCT07002099

• ZR-MTX combo for newly diagnosed primary intraocular lymphoma

  This trial tests a Rituximab, Zanubrutinib, and methotrexate cocktail plus intravitreal methotrexate in people newly diagnosed with primary intraocular lymphoma to see if it can extend the time before the disease progresses.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06973811

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.